- Home
- Publications
- Publication Search
- Publication Details
Title
Redox Regulator GLRX Is Associated With Tumor Immunity in Glioma
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-11-30
DOI
10.3389/fimmu.2020.580934
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Macrophage Polarization is Deregulated in Haemophilia
- (2019) Lynn Knowles et al. THROMBOSIS AND HAEMOSTASIS
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
- (2019) Ulrich Herrlinger et al. LANCET
- Thioredoxin, glutathione and related molecules in tumors of the nervous system
- (2019) Vasco Branco et al. CURRENT MEDICINAL CHEMISTRY
- The landscape of the mesenchymal signature in brain tumours
- (2019) Jinan Behnan et al. BRAIN
- Determining cell type abundance and expression from bulk tissues with digital cytometry
- (2019) Aaron M. Newman et al. NATURE BIOTECHNOLOGY
- Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma
- (2019) Rui-Chao Chai et al. CARCINOGENESIS
- Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma
- (2019) Zhi-liang Wang et al. Frontiers in Immunology
- Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress
- (2019) Qianqian Zhang et al. Frontiers in Pharmacology
- Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy
- (2018) Xianda Zhao et al. PHARMACOLOGY & THERAPEUTICS
- Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α
- (2018) Qirui Wang et al. Nature Communications
- Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage activation and cancer progression
- (2018) Wei Xiang et al. Nature Communications
- Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas
- (2018) Rui-Chao Chai et al. CNS Neuroscience & Therapeutics
- CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas
- (2018) Xiudong Guan et al. EBioMedicine
- Transferrin/aptamer conjugated mesoporous ruthenium nanosystem for redox-controlled and targeted chemo-photodynamic therapy of glioma
- (2018) Xufeng Zhu et al. Acta Biomaterialia
- Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor
- (2018) Huimin Hu et al. CELL
- EXTH-37. TARGETING GLIOMA STEM CELLS THROUGH COMBINED BMI1 AND EZH2 INHIBITION
- (2017) Xun Jin et al. NEURO-ONCOLOGY
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- A novel indication of thioredoxin-interacting protein as a tumor suppressor gene in malignant glioma
- (2017) Pengxing Zhang et al. Oncology Letters
- Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples
- (2017) Guanzhang Li et al. OncoImmunology
- Impaired cross-talk between the thioredoxin and glutathione systems is related to ASK-1 mediated apoptosis in neuronal cells exposed to mercury
- (2017) Vasco Branco et al. Redox Biology
- CGCG clinical practice guidelines for the management of adult diffuse gliomas
- (2016) Tao Jiang et al. CANCER LETTERS
- The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
- (2016) Hao-Yuan Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Role of Redox Status in Development of Glioblastoma
- (2016) Aleli Salazar-Ramiro et al. Frontiers in Immunology
- Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
- (2016) Zheng Wang et al. OncoImmunology
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas
- (2013) T. Doucette et al. Cancer Immunology Research
- Glutathione and Glutaredoxin Act as a Backup of Human Thioredoxin Reductase 1 to Reduce Thioredoxin 1 Preventing Cell Death by Aurothioglucose
- (2012) Yatao Du et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The role of glutathione in brain tumor drug resistance
- (2011) Donald S. Backos et al. BIOCHEMICAL PHARMACOLOGY
- Redox modification of Akt mediated by the dopaminergic neurotoxin MPTP, in mouse midbrain, leads to down-regulation of pAkt
- (2011) Lalitha Durgadoss et al. FASEB JOURNAL
- Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
- (2010) E. G. Van Meir et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
- (2009) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
- (2009) Da Wei Huang et al. Nature Protocols
- Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
- (2009) Dunyaporn Trachootham et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started